NOVO-FURAN TAB 50MG 50 MG
NITROFURANTOIN : 50 MG · DIN 00021563 · NOVOPHARM LIMITED
Health Canada status: CANCELLED POST MARKET
What is NOVO-FURAN TAB 50MG?
NOVO-FURAN TAB 50MG 50 MG contains NITROFURANTOIN : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 00021563, held by NOVOPHARM LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 10-Aug-2005. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What else is NOVO-FURAN TAB 50MG called?
The same molecule, NITROFURANTOIN, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Furadantin | Latin | Norway |
| Furadantin® | Latin | Sweden |
| Nitrofurantoin Alternova | Latin | Sweden |
| NOSTIRIAZYN | Latin | Czechia |
| ARX-Nitrofurantoin | Latin | Australia |
| AURUVEN | Latin | Czechia |
| Furadantin retard Kaps. | Latin | Austria |
| FUROLIN | Latin | Czechia |
| Nitrofurantoin BNM | Latin | Australia |
| NITROFURANTOIN OLIKLA | Latin | Czechia |
| NITROFURANTOIN | Latin | Lebanon |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 00021563 |
|---|---|
| Brand name | NOVO-FURAN TAB 50MG |
| Generic / active ingredient | NITROFURANTOIN : 50 MG |
| Manufacturer | NOVOPHARM LIMITED |
| Strength | 50 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J01XE01 NITROFURANTOIN |
| AHFS class | 08:36.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 10-Aug-2005 |
| Original market date | 1967-12-31 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 00021563 |
|---|---|
| DIN (unpadded, as printed on some documents) | 21563 |
| Brand name | NOVO-FURAN TAB 50MG |
| Active ingredient / INN | NITROFURANTOIN : 50 MG |
| ATC code | J01XE01 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J01 |
| AHFS class | 08:36.00 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | NOVOPHARM LIMITED |
Which pack is which?
| Strength on the label | 50 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
What can be used instead?
Other Canadian products sharing ATC code J01XE01 NITROFURANTOIN. 9 of 24 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-NITROFURANTOIN BID | 100 MG | CAPSULE | AURO PHARMA INC | MARKETED | DIN 02466392 |
| JAMP NITROFURANTOIN | 100 MG | CAPSULE | JAMP PHARMA CORPORATION | MARKETED | DIN 02495511 |
| JAMP NITROFURANTOIN | 50 MG | CAPSULE | JAMP PHARMA CORPORATION | MARKETED | DIN 02495503 |
| JAMP NITROFURANTOIN BID | 100 MG | CAPSULE | JAMP PHARMA CORPORATION | MARKETED | DIN 02544954 |
| NITROFURANTOIN | 100 MG | TABLET | AA PHARMA INC | MARKETED | DIN 00312738 |
| NITROFURANTOIN | 50 MG | TABLET | AA PHARMA INC | MARKETED | DIN 00319511 |
| PMS-NITROFURANTOIN BID | 100 MG | CAPSULE | PHARMASCIENCE INC | MARKETED | DIN 02455676 |
| TEVA-NITROFURANTOIN | 100 MG | CAPSULE | TEVA CANADA LIMITED | MARKETED | DIN 02231016 |
| TEVA-NITROFURANTOIN | 50 MG | CAPSULE | TEVA CANADA LIMITED | MARKETED | DIN 02231015 |
| MACROBID | 100 MG | CAPSULE | ALLERGAN INC | CANCELLED POST MARKET | DIN 02063662 |
Who else supplies NITROFURANTOIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. NITROFURANTOIN appears in 46 registered pack listings across 10 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does NITROFURANTOIN cost around the world?
NITROFURANTOIN is listed on 14 national price registers Nexara tracks, across 62 pack listings published on 13 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| South Africa | single exit price | 10 | 10 | 01 Sep 2026 |
| Czechia | max producer price (ex-factory) | 4 | 9 | 03 Sep 2026 |
| United States | acquisition | 1 | 9 | 03 Sep 2026 |
| United Kingdom | hospital | 7 | 7 | 31 Aug 2026 |
| Sweden | AIP (pharmacy purchase price) | 2 | 6 | 03 Sep 2026 |
| Australia | ex-manufacturer | 2 | 4 | 08 Sep 2026 |
| Norway | max AUP (pharmacy retail) | 1 | 4 | 07 Sep 2026 |
| Greece | producer price (ex-factory) | 3 | 3 | 03 Sep 2026 |
| Austria | KVP (Kassenverkaufspreis) | 1 | 2 | 03 Sep 2026 |
| Luxembourg | reimbursement | 2 | 2 | 05 Sep 2026 |
| Romania | max producer price | 1 | 2 | 03 Sep 2026 |
| Saudi Arabia | public | 2 | 2 | 01 Sep 2026 |
| United Arab Emirates | public | 1 | 1 | 31 Aug 2026 |
| Lebanon | public price (USD, Decision 119/1) | 1 | 1 | 02 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.